Evidence map›Paper›PMID 33817306›Full record

ArticleOpen life sciences2021

Snezana Mugosa, Zoran Todorovic, Jelena Cukic, Majda Sahman-Zaimovic, Natasa Djordjevic

Open access · goldAbstract read
In one paragraph

Article in Open life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Association ofFrontiers in cardiovascular medicine · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Pharmacogenomics Informs Cardiovascular Pharmacotherapy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  8. Impact ofPharmacogenomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Snezana MugosaFaculty of Medicine, Department of Pharmacology, University of Montenegro, 81104 Podgorica, Montenegro.
Zoran TodorovicDepartment of Pharmacology, Clinical Pharmacology Toxicology, Faculty of Medicine, University of Belgrade, University Medical Center "Bežanijska kosa", 11000 Belgrade, Serbia.
Jelena CukicDepartment for Immunology and Virology, Public Health Institute, 34000 Kragujevac, Serbia.
Majda Sahman-ZaimovicFaculty of Medicine, Department of Pharmacology, University of Montenegro, 81104 Podgorica, Montenegro.
Natasa DjordjevicDepartment of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia.
University of Montenegro · MEUniversity of Belgrade · RSUniversity of Kragujevac · RS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clopidogrel is an antiplatelet drug that displays significant interindividual variability in treatment response. Its bioavailability depends on the function of P-glycoprotein (P-gp), which is coded by a highly polymorphic

Indexed as

ABCB1clopidogrelP-glycoproteinsingle nucleotide polymorphism

Identifiers

PMID33817306
PMCPMC7968540
OpenAlexW3130412185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.